Below are the most recent publications written about "Histone-Lysine N-Methyltransferase" by people in Profiles.
-
Xu Y, Li SC, Xiao J, Liu Q, Cherukuri D, Liu Y, Mirshahidi S, Xu J, Chen X, Homa D, Olea J, Wu K, Kelly KR, Sun F, Huang R, Wang X, Wen Q, Zhang X, Ghiuzeli CM, Chong E, Abdel-Azim H, Reeves ME, Baylink DJ, Cao H, Zhong JF. Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement. Drug Resist Updat. 2025 Mar; 79:101199.
-
Frisbie VS, Hashimoto H, Xie Y, De Luna Vitorino FN, Baeza J, Nguyen T, Yuan Z, Kiselar J, Garcia BA, Debler EW. Two DOT1 enzymes cooperatively mediate efficient ubiquitin-independent histone H3 lysine 76 tri-methylation in kinetoplastids. Nat Commun. 2024 Mar 19; 15(1):2467.
-
Reis LM, Atilla H, Kannu P, Schneider A, Thompson S, Bardakjian T, Semina EV. Distinct Roles of Histone Lysine Demethylases and Methyltransferases in Developmental Eye Disease. Genes (Basel). 2023 Jan 14; 14(1).
-
Gracia-Maldonado G, Clark J, Burwinkel M, Greenslade B, Wunderlich M, Salomonis N, Leone D, Gatti E, Pierre P, Kumar AR, Lee LH. LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia. Haematologica. 2022 04 01; 107(4):803-815.
-
Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, Kentsis A, Armstrong SA. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022 02 10; 139(6):894-906.
-
Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dupéré-Richér D, Roth JS, Jing D, Casellas Román HL, Troche C, Swaroop A, Kulis M, Oyer JA, Will CM, Shen M, Riva A, Bennett RL, Ferrando AA, Hall MD, Lock RB, Licht JD. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discov. 2022 Jan; 12(1):186-203.
-
Wang J, Xiu J, Baca Y, Battaglin F, Arai H, Kawanishi N, Soni S, Zhang W, Millstein J, Salhia B, Goldberg RM, Philip PA, Seeber A, Hwang JJ, Shields AF, Marshall JL, Astsaturov I, Craig Lockhart A, Gatalica Z, Michael Korn W, Lenz HJ. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. Oncogene. 2021 07; 40(30):4894-4905.
-
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160.
-
Mubungu G, Lukute G, Makay P, Songo C, Lukusa P, Devriendt K, Lumaka A. Phenotype and growth in Sotos syndrome patient from DR Congo (Central Africa). Am J Med Genet A. 2020 07; 182(7):1572-1575.
-
Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, Kulkarni A, Chetal K, Venkatasubramanian M, Salomonis N, Kumar AR, Lee LH. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat Commun. 2020 05 12; 11(1):2369.